Meeting
2020 ASCO Virtual Scientific Program
PROSPER: Phase III randomized study comparing perioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).
Presenter
Naomi B. Haas, MD
Abramson Cancer Ctr
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Genitourinary Cancer—Kidney and Bladder
Track
Genitourinary Cancer—Kidney and Bladder
Sub Track
Kidney Cancer
Clinical Trial Registration Number
NCT03055013
Citation
J Clin Oncol 38: 2020 (suppl; abstr TPS5101)
DOI
10.1200/JCO.2020.38.15_suppl.TPS5101
Abstract #
TPS5101
Poster Bd #
170
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2024 ASCO Genitourinary Cancers Symposium
Adjuvant nivolumab monotherapy vs placebo for localized renal cell carcinoma at high risk of relapse after nephrectomy: Results from Part B of the randomized, phase 3 CheckMate 914 trial.
Speaker: Robert J. Motzer, MD
Videos & Slides
2023 ASCO Annual Meeting
Adjuvant nivolumab plus ipilimumab vs placebo for patients with localized renal cell carcinoma at high risk of relapse after nephrectomy: Subgroup analyses from the phase 3 CheckMate 914 (part A) trial.
Speaker: Robert J. Motzer, MD
Videos & Slides
2020 ASCO Virtual Scientific Program
A phase III, randomized, placebo-controlled trial of nivolumab or nivolumab plus ipilimumab in patients with localized renal cell carcinoma at high-risk of relapse after radical or partial nephrectomy (CheckMate 914).
Speaker: Axel Bex, MD, PhD
Speaker: Karen E. Hoffman, MD, MPH